Transcriptome and epigenetic analysis of healthy immune cell bloodsets
Research type
Research Study
Full title
Transcriptome and epigenetic analysis of healthy donor blood cell types for the prediction of cell identity master regulators using Mogrify Ltd's algorithms to facilitate the generation of immune cell therapies by cell conversion
IRAS ID
288948
Contact name
Emannouil Gialitakis
Contact email
Sponsor organisation
Mogrify Ltd
Duration of Study in the UK
4 years, 11 months, 1 days
Research summary
Mogrify Ltd has developed a novel algorithms that can predict the important factors responsible for cell type identity. Mogrify Ltd is now exploiting these predictions to convert any cell type (source cells) to cell types relevant for cellular therapies (target cells). For example, converting a skin fibroblast cell into a cancer specific T cell.
To carry out this study, Mogrify Ltd will obtain blood samples from the NHS Blood Transplant service (NHS BT). At Mogrify Ltd, Peripheral Blood Mononuclear Cells (PBMCs) will be separated from the blood and several immune cell subsets will be isolated by fluorescence activated cell sorting (FACS) to be subjected to DNA analysis, such as RNA sequencing and epigenetic analysis. This will generate a transcriptome and epigenetic database of each immune subtype for the company. The Mogrify Ltd algorithms will then be applied to these database to establish the regulators required for the conversion of source cells into blood cell types.
REC name
East of England - Essex Research Ethics Committee
REC reference
21/EE/0022
Date of REC Opinion
13 Jan 2021
REC opinion
Favourable Opinion